iECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM Annual Symposium

Go back to iECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM Annual Symposium
(NASDAQ: DTIL) Delayed: 6.67 +0.04 (0.60%)
Previous Close $6.63    52 Week High
Open $6.77    52 Week Low
Day High $6.92    P/E N/A 
Day Low $6.41    EPS
Volume 373,895